Imeik Technology Development Co

Imeik Technology Development Co EBITDA Margin

The EBITDA Margin of Imeik Technology Development Co (300896.SZ) as of Nov 11, 2026 is 54.29 %. In the previous year, EBITDA Margin was 77.22 % — a change of -29.70% (lower).

EBITDA Margin

54.29 %

YoY

-29.70%

Last updated:

EBITDA Margin of Imeik Technology Development Co is 2025 54.29 % . EBITDA Margin of Imeik Technology Development Co was 2024 77.22 % . It decreases by -29.70% lower compared to the previous year.

The Imeik Technology Development Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
46.75 CNY
Jan 1, 2019
64.35 CNY
Jan 1, 2020
72.50 CNY
Jan 1, 2021
78.92 CNY
Jan 1, 2022
77.98 CNY
Jan 1, 2023
76.78 CNY
Jan 1, 2024
77.22 CNY
Jan 1, 2025
54.29 CNY
The Imeik Technology Development Co EBITDA Margin history
YEAREBITDA MarginYoY
54.29 %-29.70%
77.22 %+0.57%
76.78 %-1.54%
77.98 %-1.19%
78.92 %+8.85%
72.50 %+12.66%
64.35 %+37.66%
46.75 %+9.37%
42.74 %-2.99%
44.06 %+81.25%
24.31 %-44.79%
44.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co., Ltd. generates revenue through the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. The company focuses on products like injection-type sodium hyaluronate series and polydioxanone facial implants, which are used for facial and neck skin repair in medical cosmetology, surgical repair, and metabolic disease treatment. Its self-developed products target the Chinese market, where it has established a technology transformation platform for materials such as medical chitosan and polylactic acid. The firm leverages its industrialized product lines to serve medical and cosmetic applications. The company's primary customers are healthcare providers and medical facilities in China that utilize its products for skin repair, surgical procedures, and metabolic disease management. Its product portfolio includes sodium hyaluronate series for injections, polydioxanone facial implants, and other biomedical materials like medical chitosan and polylactic acid. These products are sold under the company's own brand, with no external brands mentioned in the description. Imeik's business model centers on the industrialization of its self-developed biomedical materials, transforming research into commercial products for medical and cosmetic use. The firm's focus on recombinant proteins and peptides drives its product development, targeting applications in medical cosmetology and surgical repair. It operates within the Chinese market, where it has established a technology platform for product transformation and commercialization. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

EBITDA Margin of Imeik Technology Development Co is 54.29 % in 2025.

EBITDA Margin of Imeik Technology Development Co changed from 77.22 % to 54.29 %, representing a -29.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Imeik Technology Development Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co